Kronos Bio Inc (KRON) Actualités

Kronos Bio Announces CEO Transition and Reduction in Force

– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman...

Form EFFECT - Notice of Effectiveness

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory...

Form 8-K - Current report

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant...

Form S-3 - Registration statement under Securities Act of 1933

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong...

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV...

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

– KB-7898, a p300 KAT inhibitor, is the Company's first development candidate for autoimmune diseases and...

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and...

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum...

Kronos Bio Announces Participation in Medical and Investor Conferences in September

SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON...